Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) 

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma^[1][2][3].

Mouse IgG2a kappa

Mouse IgG2a kappa, Isotype Control

Human/Monkey

MHC class II

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (3 h) induces significantly cell lysis in Raji, Ramos and Namalwa cells^[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (1-100 nM, 48-72 h) inhibits proliferation of Raji and Daudi cell lines^[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (4-24 h) induces apoptosis in Daudi lymhoma cells^[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (48 h) induces activation of caspase-3 and AKT in a panel of lymphoma cell lines^[1].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 3 h) induces necrotic cell death in human endothelial cells and reorganization of the cytoskeleton is involved^[2].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 1 h) increases cellular ROS and loss of mitochondrial membrane potential in human endothelial cells^[2].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 3 h) induces lysosomal activation, LMP, and rupture in endothelial cells^[2].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (3-6 days) selectively suppresses the proliferation of established Epstein-Barr virus-transformed lymphoblastoid cell lines and Epstein-Barr virus-infected B cells^[3].
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (20 h) down-regulates the expression of CD23 and CD20 antigens in lymphoblastoid cell lines^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (10-300 μg, i.p., twice a week for 4 weeks) prolongs survival times in Raji injected mice models.^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3122  [NCBI]

P01903

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103.  [Content Brief]

  [2]. Stein R, et al. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood. 2006 Oct 15;108(8):2736-44.  [Content Brief]

  [3]. Aljabri A, et al. HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway. Cell Death Dis. 2019 Mar 8;10(3):235.  [Content Brief]

  [4]. Kabelitz D, et al. Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression. Cell Immunol. 1989 Apr 15;120(1):21-30.  [Content Brief]